Advanced Solid Tumor
Conditions
Brief summary
An open label, multi-center, dose-escalating study to evaluate the safety and preliminary efficacy of IMC008 in CLDN18.2 positive advanced solid tumors.
Detailed description
This study is an open label, multi-center, dose-escalating clinical study to evaluate the safety and preliminary efficacy of IMC008 in the treatment of CLDN18.2 positive advanced solid tumors. DLTs observations will be performed 28 days after IMC008 administration. During the study, regular safety meetings will be held according to the progress of the study, and recommendations will be made on dose escalation, safety of subjects and possible study change.
Interventions
DRUGIMC008
allowing 10% dose error
Sponsors
Changhai Hospital
Study design
Allocation
NA
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Dose escalation of 3 dosage groups
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Advanced gastric cancer /esophagogastric junction adenocarcinoma advanced pancreatic cancer. * Tumor tissue samples of subjects expected to be available with positive for CLDN18.2 immunohistochemistry. * The expected survival period of the subject is ≥12 weeks. * The subject needs to have at least one target lesion that can be stably evaluated. * The ECOG score is 0-1. * Subject has adequate organ and bone marrow function * All toxic reactions caused by previous anti-tumor therapy were relieved to grade 0-1. * Fertility status : Women of childbearing age or men whose sexual partners are women of childbearing age are willing to take medically approved high-efficiency contraceptive measures. * Subjects must sign and date written informed consent.
Exclusion criteria
* Pregnant and lactating women. * Known history of human immunodeficiency virus infection; acute or chronic active hepatitis B; acute or chronic active hepatitis C. Syphilis antibody positive; Epstein-Barr virus infection; CMV infection. * Serious infection that is active or poorly controlled clinically. * Uncontrollable pleural effusion, pericardial effusion, peritoneal effusion existed before enrollment. * Extensive or diffuse lung metastases or extensive or diffuse liver metastases. * Oxygen saturation ≤ 95% without oxygen inhalation. * Suffering from other research diseases that may limit their participation in this study. * Known past or current hepatic encephalopathy requiring treatment; patients with current or history of central nervous system disease. * There are heart diseases that need to be treated or hypertension that is poorly controlled by the investigator, poorly controlled after standard treatment type 2 diabetes mellitus. * Presence of any cardiac clinical symptoms or disorders. * Evidence of significant coagulopathy or other significant bleeding risk. * Received systemic steroids equivalent to \>15 mg/ day prednisone cumulatively for more than 3 days within 2 weeks prior to apheresis , excluding inhaled steroids. * Prior or concurrent occurrence of other malignancies, with the following exceptions. * Subjects who have previously received other gene therapy. * Allergic/ intolerance to lymphodepletion regimen or CRS treatment drugs or IMC008. * Subjects with severe mental disorders. * The investigator assessed the subject's inability or unwillingness to comply with the requirements of the study protocol .
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| DLT | within 28 days | To observe the incidence of dose-limiting toxicity (DLT) after IMC008 infusion |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| PFS | upto 96 weeks | To evaluate the progression-free survival of IMC008 in patients with CLDN18.2 positive advanced solid tumor |
| Objective response rate (ORR) | upto 96 weeks | The ORR is defined as the proportion of subjects with confirmed CR or confirmed PR, based on RECIST Version 1.1 |
| TRAE | up to 96 weeks | To treatment-related adverse events (TRAE) and severity |
| Lymphocyte subsets | upto 96 weeks | CAR-T cell lymphocyte subsets/phenotype, etc. |
| OS | upto 96 weeks | To evaluate the overall survival of of IMC008 in patients with CLDN18.2 positive advanced solid tumor |
| Tmax | upto 96 weeks | Tmax of CAR-T cells in the blood. |
Countries
China
Contacts
Primary ContactTianhang Luo, MD
Outcome results
None listed